secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0001104659-25-060784
Event type: regulatory
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NYSE accepts Annovis Bio's plan to regain listing compliance; 18-month cure period
--------------------------------------------------------------------------------

- Annovis received NYSE acceptance of its plan to regain compliance with minimum market capitalization and stockholders' equity standards.
- NYSE granted an 18-month period from March 26, 2025, to achieve compliance; stock remains listed subject to plan adherence.
- Annovis must provide quarterly progress updates to NYSE; business operations and SEC reporting unaffected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925060784/0001104659-25-060784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925060784/tm2518347d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-060784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer